Trafalgar International (GCAN) Income towards Parent Company (2017 - 2026)
Greater Cannabis Company (GCAN) posted quarterly Income towards Parent Company of -$33376.0 for Q1 2026, up 67.76% year-over-year from -$19895.6 in Q1 2025, and down 109.88% quarter-over-quarter from $337757.0 in Q4 2025.
Trafalgar International (GCAN) Income towards Parent Company (2017 - 2026) Analysis & Trends
Greater Cannabis Company's Income towards Parent Company history runs 10 years deep, the most recent figure standing at -$33376.0 for Q1 2026.
- In Q1 2026, Income towards Parent Company rose 67.76% year-over-year to -$33376.0; the TTM figure through Mar 2026 stood at -$122571.0 (up 48.49% YoY), while the FY2025 annual figure was -$331612.0, down 85.22% from the prior year.
- Income towards Parent Company for Q1 2026 stood at -$33376.0, down from $337757.0 in the prior quarter.
- The five-year high for Income towards Parent Company was $337757.0 in Q4 2025, with the low at -$390853.0 in Q2 2025.
- The 5-year median for Income towards Parent Company is -$46165.0 (2024), against an average of -$56105.5.
- Peak annual rise in Income towards Parent Company reached 879.18% in 2025, while the deepest fall reached 770.17% in 2025.
- Greater Cannabis Company's Income towards Parent Company stood at -$47401.0 in 2022, then rose by 1.14% to -$46861.0 in 2023, then increased by 7.5% to -$43348.0 in 2024, then surged by 879.18% to $337757.0 in 2025, then plunged by 109.88% to -$33376.0 in 2026.
- Business Quant data shows GCAN's Income towards Parent Company at -$33376.0 in Q1 2026, $337757.0 in Q4 2025, and -$36099.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.87 Bn | 42.91 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.00 Bn | 39.35 Bn | 2.15 Bn |
| 3 | Zoetis | 31.59 Bn | 29.92 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.15 Bn | 19.49 Bn | 683.80 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - |
| 10 | Trafalgar International | 236,233.75 | 236,233.75 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -33,376.00 |
| Dec 31, 2025 | 337,757.00 |
| Sep 30, 2025 | -36,099.00 |
| Jun 30, 2025 | -390,853.00 |
| Mar 31, 2025 | -103,511.00 |
| Dec 31, 2024 | -43,348.00 |
| Sep 30, 2024 | -46,165.00 |
| Jun 30, 2024 | -44,917.00 |
| Mar 31, 2024 | -44,611.00 |
| Dec 31, 2023 | -46,861.00 |
| Sep 30, 2023 | -53,430.00 |
| Jun 30, 2023 | -45,043.00 |
| Mar 31, 2023 | -43,068.00 |
| Dec 31, 2022 | -47,401.00 |
| Sep 30, 2022 | -102,776.00 |
| Jun 30, 2022 | -62,405.00 |
| Mar 31, 2022 | -147,686.00 |
| Dec 31, 2021 | -196,331.00 |
| Sep 30, 2021 | -252,278.00 |
| Jun 30, 2021 | -38,964.00 |